Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

New study explores UBA1 dysfunction in VEXAS and cancer

A new research perspective was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "UBA1 dysfunction in VEXAS and cancer."

3 Oct 2024

Key RNA pathway controlling DNA packaging and cancer progression

Inside every cell, inside every nucleus, your continued existence depends on an incredibly complicated dance. Proteins are constantly wrapping and unwrapping DNA, and even minor missteps can lead to cancer.

3 Oct 2024

Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) remains one of the most challenging hematological malignancies to treat, with relapse and refractory cases continuing to pose significant hurdles

1 Oct 2024

Nationwide study reveals radon's role in childhood leukemia

A study of more than 700 counties across multiple U.S. states found a link between childhood leukemia and levels of decaying radon gas, including those lower than the federal guideline for mitigation.

30 Sep 2024

Researchers identify a protein that recharges T cells for long-lasting cancer remission

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of combining type 1 and type 2 immunity.

30 Sep 2024

Study reveals positive correlation between type 2 immunity and long-term cancer remission

Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission.

26 Sep 2024

Why children with Down’s syndrome are predisposed to developing leukaemia

The study uncovers mechanisms linking Down syndrome to leukemia, emphasizing the role of oxidative stress and genetic alterations in fetal blood development.

26 Sep 2024

Study uncovers genetic changes linked to leukemia risk in people with Down's syndrome

People with Down's syndrome face a higher risk of developing Leukemia. Now researchers from the University of Copenhagen and Stanford University explain why, by identifying specific changes in blood cells of people with Down's syndrome.

25 Sep 2024

New approach to B-ALL treatment reduces side effects and enhances survival

Clinical trial results from St. Jude Children's Research Hospital demonstrate benefits to using genomics and early treatment response to guide risk classification of children with B-cell acute lymphoblastic leukemia (B-ALL).

24 Sep 2024

New drug combo shows promise for deeper remission in chronic leukemia

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.

24 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Study highlights physician and patient interest in climate-conscious healthcare

Concerns about the environmental impact of healthcare decisions rarely enter into conversations between patients and physicians.

13 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

Study shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatments

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other standard-of-care therapies, according to a systematic review and meta-analysis.

11 Sep 2024

$1.2 million NIH grant may help unravel the interplay between Down syndrome and myeloid leukemia

A four-year, $1.2 million grant from the National Cancer Institute of the National Institutes of Health may help researchers find new clues to the interplay between Down syndrome (DS) and myeloid leukemia (ML).

11 Sep 2024

UC's Eric Vick receives major grants to advance research into combination therapy for leukemia

The University of Cincinnati Cancer Center's Eric Vick, MD, PhD, has been awarded a nearly $215,000 Career Development Award from the Leukemia and Lymphoma Society (LLS) and a $50,000 American Society of Clinical Oncology (ASCO) Young Investigator Award to continue research into a combination therapy treatment for acute myeloid leukemia (AML).

6 Sep 2024

Study links monoclonal B-cell lymphocytosis to elevated melanoma risk

About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems.

5 Sep 2024

Investigating inflammatory memory in hematopoietic stem cells within the AML niche

A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, "Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche."

5 Sep 2024

CDK4/6 inhibitors show promise for pediatric high-grade glioma treatment

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

3 Sep 2024

Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure

Melbourne researchers have made a world first breakthrough into creating blood stem cells that closely resemble those in the human body. And the discovery could soon lead to personalized treatments for children with leukemia and bone marrow failure disorders.

2 Sep 2024